Edition:
India

BELLUS Health Inc (BLU.OQ)

BLU.OQ on NASDAQ Stock Exchange Global Select Market

7.12USD
19 Sep 2019
Change (% chg)

$-0.12 (-1.66%)
Prev Close
$7.24
Open
$7.21
Day's High
$7.21
Day's Low
$7.10
Volume
3,678
Avg. Vol
--
52-wk High
$7.88
52-wk Low
$6.90

Summary

Name Age Since Current Position

Francesco Bellini

72 2002 Chairman of the Board

Roberto Bellini

39 President, Chief Executive Officer, Director

Denis Garceau

62 Senior Vice President- Drug Development

Francois Desjardins

56 Vice President - Finance

Tony Matzouranis

43 Vice President - Business Development

Sebastien Roy

43 Corporate Secretary

Youssef Bennani

58 2017 Independent Director

Franklin Berger

69 2010 Independent Director

Clarissa Desjardins

52 2017 Independent Director

Chau Khuong

43 2018 Independent Director

Pierre Larochelle

47 2009 Independent Director

Joseph Rus

73 2009 Independent Director

Biographies

Name Description

Francesco Bellini

Dr. Francesco Bellini joined the Board of BELLUS Health (Innodia) Inc. on May 14, 2002 as a Non-executive Director. Dr Bellini is Chairman of Picchio International Inc.and is also on the board of several companies and organizations such as Molson Inc.and Industrial-Alliance Life Insurance Co. Formerly, he was Chairman and Chief Executive Officer of BioChem which he co-founded in 1986 Dr. Bellini through his private holding company, Picchio International, controls Picchio Pharma, Neurochem Inc. (Nasdaq:NRMX, TSX:NRM) and Adaltis (TSX:ADS)having the role of Chairman and Chief Executive Officer. Prior to this, Dr. Bellini was Chairman and CEO of BioChem Pharma Inc., an innovative biopharmaceutical company focused on infectious diseases and cancer, which heco-founded in 1986. In 1984, Dr. Bellini established the Biochemicals Divisionof the Institute Armand-Frappier at the Universite du Quebec, which specializes in research, manufacturing and the commercialization of fine chemicals. He headed up this unit until leaving in 1986 to co-found BioChem Pharma. Dr.Bellini is the author or co-author of some 20 patents and has published numerous articles and papers based on his research.

Roberto Bellini

Mr. Roberto Bellini is the President and Chief Executive Officer of BELLUS Health (Innodia) Inc. Mr. Bellini previously oversaw the licensing and partnering activities of BELLUS Health Inc. His experience includes responsibility for the investment and operational activities of Picchio Pharma Inc., a joint venture healthcare investment firm owned by FMRC Family Trust and Power Technology Investment Corporation. Mr. Bellini has broad ties in the community and has served on numerous fundraising committees for the following institutions: l’Institut du cancer de Montréal, the Sarah Cook Fund for the Cedars Cancer Institute, l’Institut de Gériatrie, le Musée d’art contemporain de Montréal and la Fondation Quebec Jeunes. Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.

Denis Garceau

Dr. Denis Garceau, Ph.D. is the Senior Vice President, Drug Development of BELLUS Health (Innodia) Inc. Dr. Denis Garceau directs BELLUS Health's drug development program, from toxicology to clinical evaluation through to approval of new products, and has been with the Company since March 1997. From 1986 to 1997, as a clinical scientist and product team leader for Hoechst Marion Roussel (now Sanofi-Aventis), Dr. Garceau successfully oversaw North American clinical programs and participated in global clinical development steering committees. He was responsible for developing clinical operating plans, designing clinical protocols, and supervising clinical trials. In 1985-86, Dr. Garceau completed a post-doctorate Research fellowship in Pharmacology at Merck Frosst Canada. Dr. Garceau holds a Ph.D. in Pharmacology from the Université de Montréal, and is currently a guest lecturer for the faculty of pharmacy of the Université de Montréal and Université Laval.

Francois Desjardins

Mr. Francois Desjardins CPA is the Vice President - Finance of BELLUS Health (Innodia) Inc. Mr. François Desjardins is responsible for BELLUS Health’s finance and administration functions. He joined the Company in 2003 as Director, Finance and Control and holds the position of Vice-president, Finance since 2009. Mr. Desjardins has over 20 years of experience in the biopharmaceutical industry, having held the position of Corporate Controller at BioChem Pharma for a period of six years. He is a member of the Ordre des comptables professionnels agréés du Québec (OCPAQ) and holds a Bachelor Degree of Commerce from Sherbrooke University.

Tony Matzouranis

Mr. Tony Matzouranis is the Vice President, Business Development of BELLUS Health (Innodia) Inc. Mr. Tony Matzouranis joined BELLUS Health in 2010 and currently oversees the Company’s licensing and business development activities. He has over 15 years of experience in structuring and building successful partnerships via in / out-licensing, mergers and acquisitions and alliance management. Prior to joining BELLUS Health, Mr. Matzouranis was Director of Licensing at Thallion Pharmaceuticals. From 1999 to 2007, he held Business Development positions of increasing responsibility at Caprion Pharmaceuticals. Mr. Matzouranis holds a Master’s degree in Molecular Biology from the Université du Québec à Montréal.

Sebastien Roy

Mr. Sebastien Roy serves as Corporate Secretary of the BELLUS Health Inc.

Youssef Bennani

Dr. Youssef L. Bennani serves as Independent Director of the Company. Dr. Bennani is a pharmaceutical executive and is currently Chairman of the Board of Directors of Domain Therapeutics in France and Canada. From 2013 to 2017, Dr. Bennani was Site Head and Vice-President of R&D at Vertex Pharmaceuticals Canada Inc., a research and development company. From 2011 to 2013, Dr. Bennani was Vice-President R&D at Vertex Canada. He held various positions of increasing responsibility in pharmaceutical R&D for nearly 25 years, in the USA and Canada (namely working for Ligand Pharmaceuticals, Abbott Laboratories (now Abbvie), Athersys and Vertex Pharmaceuticals). Over this span, he worked in the fields of oncology, neurology, immunology and infection. In 2011 he received an honorary degree from the Université de Montréal for his contribution to Society. His education consists of a Doctorate degree (PhD, ‘91) in chemistry from Université de Montréal and post-doctoral studies at The Scripps Research Institute in La Jolla, California, as well as an Executive-MBA (2000) from LFGSM, in Chicago, Illinois. He is an accredited Director from the Institute of Corporate Directors (ICD.D) from McGill-Rotman Schools of Business.

Franklin Berger

Mr. Franklin M. Berger is the Independent Director of BELLUS Health (Innodia) Inc. since 2010. Mr. Berger worked at Sectoral Asset Management as a senior portfolio manager on the buy-side and founder of the small-cap focused NEMO Fund from 2007 through June 2008. Mr. Berger was Managing Director, Equity Research and Senior Biotechnology Analyst for J. P. Morgan Securities from 1998 to 2003. During his years at J.P. Morgan he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities, including the Genentech initial public offering, the largest biotechnology financing to date. From 1997 to 1998, he served as a Director, Equity Research and Senior Biotechnology Analyst for Salomon Smith Barney. From 1991 to 1997, he served as a sell-side analyst for Josephthal & Co. The Wall Street Journal selected Mr. Berger as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ's 2000 Survey. In 2002, Institutional Investor Magazine ranked him on J. P. Morgan's 3rd-placed All-Star Research Team. Mr. Berger also serves on the Board of Directors of Five Prime Therapeutics, Immune Design Corp., ESSA Pharma and Proteostasis Therapeutics. Mr. Berger received a B.A. in International Relations, an M.A. in International Economics from Johns Hopkins University and an M.B.A. from Harvard University. He is a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine.

Clarissa Desjardins

Dr. Clarissa Desjardins serves as Independent Director of the Company. Dr. Clarissa Desjardins founded Clementia Pharmaceuticals Inc. in 2011 and has served as the company’s chief executive officer since then. Prior to Clementia, she was CEO at the Centre d’excellence en médecine personnalisée (CEPMED), a Montreal-based federally and privately funded non-profit enterprise created to promote personalized medicine. Dr. Desjardins is an award-winning entrepreneur with more than 18 years of biotechnology experience. She has founded three successful biotech companies, leading all aspects of company creation including conception and financing. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. Dr. Desjardins also co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was executive vice-president of Corporate Development. Dr. Desjardins is the recipient of the 2018 Bloom Burton Award for her contribution to Canada’s innovative healthcare industry, the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of the top young Canadians likely to influence the future by the Globe and Mail. She has been a board member of numerous companies including the scientific advisory council of the Canadian Academy of Sciences. Dr. Desjardins earned a doctorate in Neurology and Neurosurgery from McGill University’s Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre

Chau Khuong

Mr. Chau Q. Khuong serves as Independent Director of the Company. Mr. Khuong is a Partner on the private equity team of OrbiMed. Over his venture capital career, Mr. Khuong has invested in drugs and therapeutic devices across a range of disease areas from oncology to infectious diseases to ophthalmology. Prior to OrbiMed, he developed skills in start-up operations and business development at Veritas Medicine, Inc. and in basic immunology research at the Yale School of Medicine and Massachusetts General Hospital. Mr. Khuong holds a Bachelor of Science in molecular, cellular and developmental biology and Master of Public Health (MPH) with concentration in infectious disease, both from Yale University.

Pierre Larochelle

Mr. Pierre Larochelle is the Independent Director of BELLUS Health (Innodia) Inc. since 2009. Pierre Larochelle has served as a Director of BELLUS Health since June 2009. Mr. Larochelle joined Power Corporation of Canada in March 2009 as Vice-President, Investments. Prior to joining Power Corporation of Canada, Mr. Larochelle was President and Chief Executive Officer at Adaltis, a position he held between November 2003 and February 2009. Previously, he also held the positions of Vice-President, Business Development at Picchio Pharma Inc. and Vice-President, Mergers and Acquisitions for Credit Suisse First Boston in London, England. Mr. Larochelle started his career as a lawyer, at the Montreal offices of Ogilvy Renault. Mr. Larochelle serves on the Board of Directors of Sagard Capital, Sagard SAS, Victoria Square Ventures and Lumenpulse Inc. He holds a law degree from Université de Montréal, a masters degree in international business law from McGill University and a MBA degree from INSEAD in Fontainebleau, France.

Joseph Rus

Mr. Joseph Rus is the Independent Director of BELLUS Health (Innodia) Inc. since 2009. Mr. Joseph Rus joined Shire Pharmaceuticals in 1999, following 25 years of experience with two major pharmaceutical companies in both Canadian and Global assignments. Working out of the Shire United Kingdom offices he was charged with establishing Shire’s European foothold. This was accomplished in 2000, with the acquisition of profitable companies in Germany, Italy, France and Spain. After the acquisition of Roberts Pharmaceuticals, he returned to Canada to manage the Canadian Operation. Subsequent to the Biochem acquisition, Mr. Rus moved to Montreal as President and CEO of Shire-Biochem in 2001. In the year 2002, Mr. Rus returned to the U.K. as Head of Shire’s International Operations (all countries except USA). Since that time, Mr. Rus also serves on Shire’s Executive Committee as well as the Portfolio Review Committee. In 2006 Mr. Rus was charged with the responsibility of establishing affiliates in the increasingly important Emerging Markets, and by 2009 affiliates were open in Brazil, Mexico, Argentina, Russia, Australia and Japan. Additionally, the management of the Royalty Revenue Investment Portfolio and Intellectual Property Transition were managed out of Shire’s Dublin, Ireland Offices, under Mr. Rus’ leadership. During his tenure at Roche, Mr. Rus was responsible for the Canadian Pharmaceutical business (1994-1998), prior to this, between 1985 -1994 he assumed positions of increasing responsibility including Country Management from the Roche Headquarters in Basel, Switzerland. Germany, Italy, Greece, Portugal and later Canada delivered significant profitability levels to Roche on a revenue of $1.5 billion. In 1972, Mr. Rus began his career in Canada with Warner Lambert. Over the years, he acquired broad experience in the Pharmaceutical Industry, rising rapidly in positions of Sales Management, Marketing, Operations, Clinical Research and Business Development.